There are currently 443 clinical trials in Memphis, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including St. Jude Children's Research Hospital, Saint Jude Children's Research Hospital, Baptist Memorial Hospital and Cancer Center-Memphis and University of Tennessee Health Science Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)
NCT03999983
Recruiting
A retrospective and prospective registry of patients admitted for stroke and evidence of Vertebral Artery Origin Stenosis (VAOS).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/10/2025
Locations: Semmes Murphey Clinic, Memphis, Tennessee
Conditions: Vertebral Artery Stenosis
Register for Updates
Making Healthy Habits Stick
NCT06745180
Recruiting
The aim of this project is to help increase physical activity maintenance in cancer survivors who are more likely to experience health disparities and social disadvantages.
Gender:
FEMALE
Ages:
Between 19 years and 89 years
Trial Updated:
02/07/2025
Locations: University of Tennessee Health Science Center, Memphis, Tennessee
Conditions: Cancer, Physical Activity, Cancer Survivor, Cancer Survivorship
Register for Updates
Pediatric Oncology Recovery Trial After Surgery
NCT04344899
Recruiting
Pediatric Oncologic Recovery Trial After Surgery (PORTS) trial is an investigator-initiated, multicenter, multidisciplinary prospective case-control study of the implementation of an Enhanced Recovery After Surgery (ERAS) protocol at five tertiary-care pediatric hospitals in pediatric patients undergoing abdominal or retroperitoneal surgical resections for cancer. A pilot phase will determine characteristics of a successful protocol implementation and an exploratory phase plans to examine adhere... Read More
Gender:
ALL
Ages:
Between 1 month and 18 years
Trial Updated:
02/06/2025
Locations: St Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Pelvic Cancer
Register for Updates
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
NCT03755804
Recruiting
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxo... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/06/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Hodgkin Lymphoma
Register for Updates
Characterizing Sleep Among Long-term Survivors of Childhood Cancer
NCT05480904
Recruiting
The patients are being asked to take part in this clinical trial because they received cancer treatment as a child at St. Jude. The study comprehensively examines sleep among three distinct diagnostic groups of survivors in the SJLIFE cohort: ALL, CNS tumors, and non-CNS solid tumors. Primary Objective The primary aim of this protocol is to estimate the prevalence of various sleep disorders among long-term survivors of childhood ALL, CNS tumors, and non- CNS solid tumors. Exploratory Objectiv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: ALL, Adult, CNS Tumor, Solid Tumor
Register for Updates
Gastric Feeding Versus Transpyloric Feeding in Infants with Severe Bronchopulmonary Dysplasia, a Crossover Study
NCT06821776
Recruiting
Hospitalized infants with severe bronchopulmonary dysplasia (BPD) and feeding intolerance will be randomized to 2 weeks of continuous gastric feeding or continuous transpyoloric feeding. Subjects will crossover after 2 weeks and receive 4 weeks of each feeding mode. Respiratory status will be assessed to determine the optimal feeding mode for each infant.
Gender:
ALL
Ages:
Between 1 month and 1 year
Trial Updated:
02/06/2025
Locations: Le Bonheur Children's Hospital, Memphis, Tennessee
Conditions: Bronchopulmonary Dysplasia, Feeding Intolerance
Register for Updates
Two Dose Levels of Privigen in Pediatric CIDP
NCT03684018
Recruiting
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
02/06/2025
Locations: Le Bonheur Children's Hospital, Memphis, Tennessee
Conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Register for Updates
A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)
NCT05600426
Recruiting
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a... Read More
Gender:
ALL
Ages:
Between 0 years and 25 years
Trial Updated:
02/05/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Severe Aplastic Anemia
Register for Updates
Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer
NCT05550948
Recruiting
Survivors of childhood cancer are at greater risk for long-term cognitive impairments that include attention, executive function, intelligence, memory, and processing speed. The participants are a survivor of acute lymphoblastic leukemia (ALL) or Hodgkin's lymphoma (HL). Because of your treatment the participant may have developed trouble with thinking and learning. Primary Objective To evaluate the feasibility of using home-based tPBM paired with remote cognitive training to improve cognitive... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: ALL, Hodgkin Lymphoma, Cancer, Survivorship
Register for Updates
Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
NCT06480526
Recruiting
The study participant is being asked to be in a research study called LEGACY, because you were treated for high-risk neuroblastoma (HR-NBL). Primary Objective To determine the feasibility of conducting comprehensive evaluations, leveraging the established SJLIFE (St. Jude Lifetime Cohort Study) study infrastructure, in survivors of HR-NBL (high-risk neuroblastoma) who are greater than 2 years from completion of contemporary therapy and were previously treated at SJCRH (St. Jude Children's Rese... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
02/03/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: High-risk Neuroblastoma
Register for Updates
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543
Recruiting
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: University of Tennessee -- Memphis, Memphis, Tennessee
Conditions: Colorectal Cancer
Register for Updates
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
NCT06450041
Recruiting
This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
Gender:
ALL
Ages:
Between 1 year and 31 years
Trial Updated:
01/30/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma
Register for Updates